BTI615 / Chengdu Brilliant Pharma - LARVOL DELTA

Efficacy of BTI615 on malignant cells expansion and bone marrow fibrosis in a myelofibrosis mice model. (ASCO 2025) - "Here we verified that BTI615, a synthetic active TGF-β modulating peptide, rescued malignant cells expansion and bone marrow fibrosis to restore hematopoiesis in a romiplostim-induced MF model. Given its effective suppression on hyperplasia of atypical megakaryocytes, inflammation, marrow fibrosis and the ultimate recovery of hematopoietic function via modulating TGF-β signaling, BTI615 has a great potential to be the next generation therapeutic approach for MF."

Preclinical • Fibrosis • Immunology • Myelofibrosis • TGFB1